ASTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Astrana Health Inc (ASTH) is not a strong buy at this time for a beginner investor with a long-term focus. While the stock has shown recent price growth and has positive analyst ratings, the financial performance in the latest quarter, particularly the significant drop in net income and EPS, raises concerns. Additionally, technical indicators and trading sentiment do not suggest a compelling entry point currently.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is in the neutral zone at 71.268, suggesting no clear overbought or oversold condition. Moving averages are converging, showing no strong trend. Key resistance levels are close to the current price, with R1 at 25.168 and R2 at 25.735, which may limit upward movement in the short term.
Analysts maintain a Buy rating and have raised price targets recently, citing the company's emergence as a larger value-based care platform. Revenue growth of 42.89% YoY in Q4 2025 is a positive indicator.
No recent news or significant trading trends from hedge funds or insiders. The stock has a 30% chance of declining in the next day and week based on historical patterns.
In Q4 2025, revenue increased by 42.89% YoY to $950.53 million, but net income dropped by -186.30% YoY to $5.99 million. EPS also fell by -180.00% YoY to 0.12, indicating profitability challenges. Gross margin improved by 29.83% YoY to 8.27.
Analysts maintain a Buy rating. Truist raised the price target to $38 from $37, citing the company's growth as a value-based care platform. BTIG lowered the price target to $40 from $45 due to macro challenges but retained a Buy rating.
